Фармакоэкономический анализ пятилетней поддерживающей терапии больных шизофренией зелдоксом, рисполептом, сероквелем и солианом

Е.Б. Любов, Чапурин Сергей Анатольевич, Чурилин Юрий Юрьевич · Социальная и клиническая психиатрия · 2007

Objective: Comparison of results of the pharmacoeconomic modeling of the process of a 5-year maintenance treatment of schizophrenic patients with Zeldox (Ziprasidone), Rispolept (Risperidone), Seroquel (Quetiapine) and Solian (Amisulpride). Material and method: pharmacoeconomic prediction (cost utility method) based on the Markov modeling. Results: Seroquel seems to have highest utility, while Rispolept and Solian have lowest one. Seroquel is superior to Rispolept and Solian as far as safety is concerned in long-term use and it dominates in the cost-utility aspect in the target subpopulation of chronic patients with predicted risk of extrapyramidal side effects and body weight gain, and in those suffering from the latter while using other atypical antipsychotics. Sensitivity analysis of the model used point to stability of results.

Cited by 0 works.

Authors